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Abstract
IL-32 is a newly described cytokine in the human found to be an
in vitro inducer of tumor necrosis factor alpha (TNFα). We
examined the in vivo relationship between IL-32 and TNFα, and
the pathologic role of IL-32 in the TNFα-related diseases –
arthritis and colitis. We demonstrated by quantitative PCR assay
that IL-32 mRNA was expressed in the lymphoid tissues, and in
stimulated peripheral T cells, monocytes, and B cells. Activated
T cells were important for IL-32 mRNA expression in monocytes
and B cells. Interestingly, TNFα reciprocally induced IL-32
mRNA expression in T cells, monocyte-derived dendritic cells,
and synovial fibroblasts. Moreover, IL-32 mRNA expression was
prominent in the synovial tissues of rheumatoid arthritis patients,
especially in synovial-infiltrated lymphocytes by in situ
hybridization. To examine the in vivo relationship of IL-32 and
TNFα, we prepared an overexpression model mouse of human
IL-32β (BM-hIL-32) by bone marrow transplantation.
Splenocytes of BM-hIL-32 mice showed increased expression
and secretion of TNFα, IL-1β, and IL-6 especially in response to
lipopolysaccharide stimulation. Moreover, serum TNFα
concentration showed a clear increase in BM-hIL-32 mice. Cell-
sorting analysis of splenocytes showed that the expression of
TNFα was increased in resting F4/80+ macrophages, and the
expression of TNFα, IL-1β and IL-6 was increased in
lipopolysaccharide-stimulated F4/80+  macrophages and
CD11c+  dendritic cells. In fact, BM-hIL-32 mice showed
exacerbation of collagen-antibody-induced arthritis and
trinitrobenzen sulfonic acid-induced colitis. In addition, the
transfer of hIL-32β-producing CD4+  T cells significantly
exacerbated collagen-induced arthritis, and a TNFα blockade
cancelled the exacerbating effects of hIL-32β. We therefore
conclude that IL-32 is closely associated with TNFα, and
contributes to the exacerbation of TNFα-related inflammatory
arthritis and colitis.
Introduction
Tumor necrosis factor alpha (TNFα) is a potent proinflamma-
tory cytokine and is related to several inflammatory diseases
such as rheumatoid arthritis (RA) and inflammatory bowel dis-
eases (IBDs). RA is a persistent inflammatory arthritis and is
thought to be an autoimmune disease. Inflammation of the
joints results in the destruction of cartilage and bone early in
the course of the disease. Although the pathogenesis of RA is
still unclear and may be heterogeneous, several proinflamma-
tory cytokines participate in promoting the inflammation of the
joints. TNFα facilitates arthritis and the destruction of bone [1-
4]. TNFα is secreted by several kinds of inflammatory cells,
including macrophages, monocytes, T cells, and synovial
fibroblasts. TNFα induces other inflammatory cytokines and
promotes osteoclastogenesis to destroy the bones. TNFα
transgenic mice develop inflammatory arthritis spontaneously
[1]. Moreover, TNFα inhibition decreases the severity of arthri-
tis, and both monoclonal antibodies to TNFα and a soluble
BM-hIL-32 = overexpression model of human IL-32β model by bone marrow transplantation; Con A = concanavalin A; ELISA = enzyme-linked immu-
nosorbent assay; FCS = fetal calf serum; GFP = green fluorescent protein; H & E = hematoxylin and eosin; hIL-32 = human interleukin-32; IBD = 
inflammatory bowel disease; IL = interleukin; LPS = lipopolysaccharide; mAb = monoclonal antibody; MACS = magnetic-activated cell sorting; MHC 
= major histocompatibility comprex; MoDC = monocyte-derived dendritic cell; PBMC = peripheral blood mononuclear cell; PBS = phosphate-buff-
ered saline; PCR = polymerase chain reaction; RA = rheumatoid arthritis; RT = reverse transcriptase; TNBS = trinitrobenzen sulfonic acid; TCR = T-
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tumor necrosis factor receptor analog have been used as
effective therapies for RA and for other types of inflammatory
arthritis [5-8]. In addition, other cytokines, such as IL-1 and IL-
6, are also known to be important participants, and the inhibi-
tion of these cytokines has been a part of the effective thera-
pies for RA in clinical practice [4].
TNFα plays a pivotal role in the pathogenesis of IBDs including
Crohn's disease. The murine model of IBD, trinitrobenzen sul-
fonic acid (TNBS)-induced colitis, is exacerbated in TNFα
transgenic mice [9], and is ameliorated in tumor necrosis fac-
tor receptor 2-knockout mice [10]. In the clinical setting, TNFα
blockade by infliximab is demonstrated as a useful therapy for
Crohn's disease [11]. The mechanisms of TNFα production in
these inflammatory diseases, however, remain to be clarified.
Human IL-32 (hIL-32) has been reported as a novel cytokine.
IL-32 was cloned as a gene induced by IL-18 and was formerly
known as natural killer cell transcript 4 [12,13]. IL-32 induces
TNFα secretion in human monocyte and mouse macrophage
cell lines. hIL-32 has four splice variants, IL-32α, IL-32β, IL-
32γ, and IL-32δ. IL-32α is present in intracellular locations,
and IL-32β is secreted from the cells. IL-32α and IL-32β are
thought to be the major expressed variants. The sequences of
IL-32β and IL-32γ are quite similar. A mouse homolog of IL-32
has not so far been reported.
IL-32 is expressed in lymphoid tissues, such as the thymus, the
spleen, and the intestines. Human natural killer cells increase
the secretion of IL-32 by IL-18 + IL-12 stimulation, and human
peripheral blood mononuclear cells (PBMCs) also secrete IL-
32 after stimulation with concanavalin A (Con A). The fact that
the IL-32-related cytokines, TNFα and IL-18, show a close cor-
relation with arthritis [14,15] implies that IL-32 has a patho-
logic role in inflammatory diseases. Indeed, the expression of
IL-32 is increased in synovial tissues from RA patients, and the
administration of recombinant IL-32γ into mice joints provokes
cellular infiltration in the joint spaces [16]. We choose IL-32β
for our assay, because IL-32β was reported as a dominant var-
iant and as a secreted protein from the cells, and the
sequences of IL-32β and IL-32γ were basically similar [13].
We demonstrated that IL-32 is expressed in various lymphoid
cells, and in the synovial-infiltrated lymphocytes of RA patients.
In vivo, we prepared overexpression model mice of human IL-
32β by bone marrow transplantation (BM-hIL32). The expres-
sion and secretion of TNFα were increased in resting F4/80+
splenic macrophages of BM-hIL-32 mice, and the expression
and secretion of TNFα, IL-1β, and IL-6 were increased in F4/
80+ splenic macrophages and CD11c+ splenic dendritic cells
after lipopolysaccharide (LPS) stimulation. In fact, the murine
models of TNFα-related diseases, TNBS-induced colitis and
collagen antibody-induced arthritis, were exacerbated in BM-
hIL-32 mice. Furthermore, hIL-32β-transduced CD4+ T cells
showed marked exacerbation of collagen-induced arthritis, an
effect that was, in part, cancelled by TNFα blockade. Our data
indicate that IL-32 is closely associated with TNFα and that it
plays a role in the exacerbation of inflammatory diseases.
Materials and methods
Mice
DBA/1J mice and C57BL/6 mice were obtained from Japan
SLC (Shizuoka, Japan). All mice were used at 6–8 weeks of
age. All animal experiments were conducted in accordance
with institutional and national guidelines.
Collagen-induced arthritis and collagen antibody 
induced arthritis
Collagen-induced arthritis was induced as described previ-
ously [17]. In short, bovine type II collagen (Chondrex, Red-
mond, WA, USA) was emulsified with an equal volume of
Complete Freund's adjuvant (Chondrex). DBA/1J mice were
immunized with 50 μg bovine type II collagen intradermally at
the base of the tail on day 0 and day 21. Collagen antibody-
induced arthritis was induced by intravenous injection of 2 mg
arthrogen mAb cocktail to type II collagen, and 3 days later by
intraperitoneal injection of 50 μg LPS (Chondrex), as
described previously [18]. The arthritis score was determined
by erythema, swelling, or ankylosis per paw, as described else-
where [19]. In some experiments, 50 μg/day etanercept
(Wyeth, Madison, NJ, USA) was administered intraperitoneally
for 14 days after CD4+ T-cell transfer. The antiarthritic effect of
human tumor necrosis factor receptor Fc fusion protein
(etanercept) was demonstrated in collagen-immunized mice
[8]. Sacrifice was performed 40 days after the first immuniza-
tion in collagen-induced arthritis mice.
Trinitrobenzen sulfonic acid-induced colitis
TNBS (Wako, Osaka, Japan) was diluted to a final concentra-
tion of 1.75% with 50% ethanol and PBS. C57BL/6 mice
were anesthetized with 500 μg nembutal (Dainippon Pharma-
ceutical, Osaka, Japan) by intraperitoneal injection, and 100 μl
(1.75 mg) TNBS was administered into the rectum through a
4 cm inserted catheter, as previously described [10]. The body
weight was measured daily, and mice were sacrificed 4 days
after induction for further analysis. One group of BM-hIL-32
mice were administered 200 μg/day etanercept (Wyeth) intra-
peritoneally after induction of colitis; other mice were adminis-
tered the same volume of PBS each day.
Cytokines and cell lines
Recombinant human TNFα, IL-12, IL-18, IL-23, granulocyte-
macrophage colony-stimulating factor, and IL-4 were obtained
from R&D Systems (Minneapolis, MN, USA). The human 293T
cell line and the mouse macrophage cell line, Raw 267.4, were
obtained from ATCC (Manassas, VA, USA). Cell lines and pri-
mary cells were cultured with RPMI 1640 medium supple-
mented with 10% FCS, 2 mM γ-glutamine, 100 U/ml penicillin,
100 μg/ml streptomycin, and 5 × 10-5M 2-mercapto ethanol.
Recombinant human cytokines were added to the cultureAvailable online http://arthritis-research.com/content/8/6/R166
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medium as follows: 50 ng/ml human TNFα, 50 ng/ml hIL-23,
50 ng/ml IL-18, and 10 ng/ml IL-12 (R&D Systems).
Monoclonal antibodies and flow cytometry
Monoclonal antibodies to mouse CD3, CD4, CD8, CD11c,
CD19, and F4/80 were obtained from BD Biosciences (San
Jose, CA, USA). Cell sorting was performed on a FACSVan-
tage system (Becton Dickinson Immunocytometry Systems,
Mountain View, CA, USA), and analysis was performed on an
EPICS flow cytometer (Beckman Coulter, Fullerton, CA, USA).
Synovial tissue samples from rheumatoid arthritis 
patients
Synovial membranes and synovial fibroblasts were obtained
from patients with RA satisfying the diagnostic criteria of the
American College of Rheumatology [20]. We sampled patho-
logical joint synovial tissues from individuals with RA who
underwent arthroplasty surgery. Informed consent was
obtained from all patients. Synovial fibroblasts were isolated
as formally described [21]. In brief, the collected synovial tis-
sues were digested with collagenase type IV, hyaluronidase,
and DNase I (Sigma-Aldrich Corporate, St. Louis, MO, USA),
and were passed through a metal screen to prepare isolated
cells.
Peripheral blood mononuclear cells
Human PBMCs were isolated from the leukocytes of a healthy
donor by Ficoll-Paque (Amersham Pharmacia, Dübendorf,
Switzerland). In some experiments, PBMCs were subjected to
negative selection with MACS (magnetic-activated cell sort-
ing) using anti-human CD3 mAb (Miltenyi Biotec, Auburn, CA,
USA). PBMCs were stimulated with Con A or plate-coated
anti-human CD3 antibodies and anti-human CD28 antibodies
(R&D Systems). The stimulated cells were incubated for 24
hours and were separated by MACS with anti-human CD4
mAb, anti-human CD8 mAb, anti-human CD14 mAb, and anti-
human CD20 mAb (BD PharMingen, San Diego, CA, USA).
Human monocyte-derived dendritic cells (MoDCs) were iso-
lated and cultured as previously described [22]. Briefly,
CD14+ cells were isolated from human PBMCs by the MACS
procedure and were cultured with 50 ng/ml recombinant
human granulocyte-macrophage colony-stimulating factor and
IL-4. After 7 days of incubation, MoDCs were cultured with 25
ng/ml LPS (Sigma) or 50 ng/ml human TNFα for 24 hours.
Preparation of retroviral constructs of IL-32β
hIL-32β cDNA was isolated from the human cDNA library
according to the reported nucleotide sequence (GenBank:
NM 001012631) [13]. The full-length fragments were sub-
cloned into the retrovirus vector pMIG [23]. In some experi-
ments, a cell line was cultured with 1 ml of the supernatant of
hIL-32β or mock-transfected (pMIG-transfected) 293T cells in
the presence of 5 μg/ml polymixin B (Pfizer, New York, NY,
USA) for 24 hours [24].
Production of retroviral supernatants and retroviral 
transduction
Total splenocytes were cultured for 48 hours in the presence
of Con A (10 μg/ml) and mIL-2 (50 ng/ml) (R&D Systems).
Retroviral supernatants were obtained by transfection of pMIG
or pMIG-hIL-32β into PLAT-E packaging cell lines using
FuGENE 6 transfection reagent (Roche Diagnostic System,
Somerville, NJ, USA) [25]. For the detection of green fluores-
cent protein (GFP)-positive cells, we used an EPICS flow
cytometer (Beckman Coulter, Fullerton, CA, USA).
Gene transduction to mouse splenocytes and adoptive 
transfer
Retroviral gene transduction was performed as described
[26,27]. Briefly, Falcon 24-well plates (BD Biosciences) were
coated with the recombinant human fibronectin fragment
CH296 (Retronectin; Takara, Otsu, Japan). The viral superna-
tant was preloaded into each well of the CH296-coated plate,
and the plate was spun at 2400 rpm for 3 hours at room tem-
perature. This procedure was repeated three times. The viral
supernatant was washed away, and Con A-stimulated spleno-
cytes were placed into each well (1 × 106 per well). Cells were
cultured for 48 hours to allow infection to occur [23,28].
A CD4+ T-cell population was prepared by negative selection
by MACS with anti-CD19 mAb, anti-CD11c mAb, and anti-
CD8a mAb (BD PharMingen). The gene-transduced CD4+ T
cells were suspended in PBS and injected intravenously (1 ×
107) 23 days after the first immunization of bovine type II col-
lagen.
Bone marrow precursor cell isolation, infection, and 
transfer
Bone marrow precursor cell isolation, retrovirus infection, and
transfer were performed as described previously [29]. In brief,
DBA/1J mice or C57BL/6 mice were treated with 5 mg/body
5-fluorouracil (Sigma) dissolved in PBS. After 5 days, bone
marrow cells were harvested and cultured with 50 ng/ml mIL-
3, mIL-6, and mouse stem cell factor (R&D Systems) for 48
hours. The bone marrow cells were then spin-infected with the
retrovirus supernatants using 16 μg/ml polybrene for 90 min-
utes at 2400 rpm and 25°C. Recipient mice, which were the
same strain as the donor mice, were treated by 700 rad whole-
body radiation and were injected with 1 × 106 bone marrow
cells intravenously. To avoid wasting of the recipient mice due
to the overexpression of inflammatory cytokine, the GFP-posi-
tive cells among the bone marrow cells were adjusted to
around 10% before transplantation. Recipient mice were
maintained for 6–9 weeks until analysis. In some experiments,
splenocytes derived from bone marrow transplantation DBA/
1J mice were cultured for 48 hours with RPMI 1640 medium
containing 10% FCS and 1 μg/ml LPS (Sigma) for further
analysis.Arthritis Research & Therapy    Vol 8 No 6    Shoda et al.
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RT-PCR and quantitative PCR
RNA of the cells was extracted using the RNeasy Micro Kit
and RNeasy Mini Kit (Qiagen, Valencia, CA, USA). RNA from
the tissues was isolated by the acid guanidinium thiocyanate-
phenol-chloroform extraction method using ISOGEN (Nippon
Gene, Tokyo, Japan). RNA was reverse-transcribed to cDNA
with random primers (Invitrogen, Carlsbad, CA, USA) and
Superscript III according to the manufacturer's protocol (Invit-
rogen). Quantitative real-time PCR analysis was performed by
the Assay-on-Demand TaqMan probe (Hs00992441_m1 for
natural killer cell transcript 4) using the ABI PRISM 7900 sys-
tem (Applied Biosystems, Branchburg, NJ, USA) in the analy-
sis of tissue expression, and using the iCycler system (Bio-rad,
Hercules, CA, USA) in the analysis of cellular expression. The
TaqMan gene expression assay was performed according to
the manufacturer's protocol; a 20 μl reaction mixture con-
tained 1 μl of 20 TaqMan gene expression assay, 9 μl cDNA
template, and 10 μl of 2x TaqMan universal master mix. For
analyzing cellular expression, the PCR mixture consisted of 25
μl SYBR Green Master Mix (Qiagen), 15 pmol forward and
reverse primers, and cDNA samples for a total volume of 50 μl.
The results of real-time PCR are shown in terms of relative
expression compared with β-actin. The primers used in the
real-time PCR are presented in Table 1. The indicated primers
and probes for IL-32 were designed for detecting all known
isoforms of hIL-32.
Immunoassays of mouse cytokines
Concentrations of mouse TNFα, IL-1β, and IL-6 in sera and
culture supernatants were measured by sandwich ELISA
according to the manufacturer's protocol (BD Pharmingen).
An automatic microplate reader (Bio-rad 550; Bio-rad) was
used to measure the optical density.
Histopathology
Tissue samples of RA patients and sacrificed mice were
embedded in paraffin wax after 10% formaldehyde fixation and
decalcification. The sections were stained with H & E. Synovial
tissues were graded by mononuclear cell infiltration, by pan-
nus formation, and by cartilage erosion as described previ-
ously [30]. Inflammation of the colon was graded by the extent,
cellular infiltration, ulceration, and regeneration as described
elsewhere [10].
In situ hybridization
In situ hybridization of the synovial tissue samples was per-
formed as previously described [31]. Single-stranded sense
and antisense probes were generated by in vitro transcription
from the cDNA encoding hIL-32β, nucleotides 30–340 (311
base pairs), which was marked by digoxinogen using the DIG
RNA Labeling Mix (Roche, Basel, Switzerland). The sequence
of the hIL-32 probe was complementary to the unique
sequence of hIL-32β, because IL-32β is the dominant secret-
ing isoform of IL-32. This probe could detect the cDNA of hIL-
32β and IL-32γ, but not of IL-32α or IL-32δ, by Southern
hybridization (data not shown). Hybridization was performed
with probes at a concentration of 100 ng/ml at 60°C for 16
hours. Anti-DIG AP conjugate (Roche) was used as the detec-
tion antibody, and coloring reactions were performed with BM
purple AP substrate (Roche). The sections were counter-
stained with Kernechtrot stain solution (Mutoh, Tokyo, Japan),
were dehydrated, and were mounted with Malinol (Mutoh). We
Table 1
Primers used in the real-time PCR
Human IL-32 Sense 5'-TGAGGAGCAGCACCCAGAGC-3'
Antisense 5'-CCGTAGGACTGGAAAGAGGA-3'
Human TNFα Sense 5'-GTCTCCTACCAGACCAAG-3'
Antisense 5'-CAAAGTAGACCTGCCCAGACTC-3'
Human β-actin Sense 5'-TTCCTGGGCATGGAGTCCT-3'
Antisense 5'-AGGAGGAGCAATGATCTTGATC-3'
Mouse TNFα Sense 5'-CATCTTCTCAAAATTCGAG-3'
Antisense 5'-TGGGAGTAGACAAGGTACAACCC-3'
Mouse IL-1β Sense 5'-CAACCAACAAGTGATATTCTCCATG-3'
Antisense 5'-GATCCACACTCTCCAGCTGCA-3'
Mouse IL-6 Sense 5'-CACTTCACAAGTCGGAGGCTTA-3'
Antisense 5'-GCAAGTGCATCATCGTTGTTG-3'
Mouse β-actin Sense 5'-AGAGGGAAATCGTGCGTGAC-3'
Antisense 5'-CAATAGTGATGACCTGGCCGT-3'
TNFα, tumor necrosis factor alpha.Available online http://arthritis-research.com/content/8/6/R166
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also examined control probes, which yielded no specific
hybridization (data not shown).
Statistical analysis
Data are expressed as the mean ± standard deviation. All
results were obtained from at least three independent experi-
ments. Statistical significance was determined by the Mann-
Whitney U test, and P < 0.05 was considered significant.
Results
Increased IL-32 expression in activated human 
peripheral blood mononuclear cells
A previous study showed that IL-32 was expressed in the thy-
mus, the spleen, the intestines, and Con A-stimulated PBMCs
by northern blotting and electrochemiluminescence [13]. At
first we examined the tissue and cellular expression of IL-32 by
quantitative real-time PCR. The tissue expression of IL-32 was
prominent in the spleen, the lung, and the peripheral white
blood cells (Figure 1a). IL-32 was therefore expressed mainly
in the lymphoid tissues and leukocytes.
Since human PBMCs secrete IL-32 by means of the stimula-
tion of Con A [13], we investigated which components of
PBMCs expressed IL-32 during both the resting and activated
states. CD3+ T cells expressed significant amounts of IL-32
without stimulation, and CD3+ T cells, CD14+ monocytes, and
CD20+ B cells increased IL-32 expression after Con A stimu-
lation (Figure 1b). The cellular IL-32 expression was essentially
the same in the case of anti-CD3 antibody and anti-CD28 anti-
body stimulation, which stimulated T cells specifically (Figure
1b). Monocytes or B cells, however, had lower IL-32 expres-
sion when they were cultured without CD3+ T cells (Figure
1c). Activated T cells therefore have the capability of inducing
IL-32 expression in monocytes and B cells.
Figure 1
Examination of tissue and cell expression of IL-32 by quantitative real-time PCR Examination of tissue and cell expression of IL-32 by quantitative real-time PCR. (a) Tissue expression of IL-32. WBC, white blood cells. (b) Human 
peripheral blood mononuclear cells (PBMCs) expressed IL-32. PBMCs were cultured with or without concanavalin A. PBMCs were also stimulated 
by immobilized anti-human CD3 and anti-human CD28 antibodies. Cont, control. (c) IL-32 expression of monocytes and B cells after the depletion of 
CD3+ cells. (d) Peripheral CD4+ T cells were cultured with the indicated inflammatory cytokines for 24 hours. (e) Human monocyte-derived dendritic 
cells (MoDCs) were cultured with lipopolysaccharide (LPS) or tumor necrosis factor alpha (TNFα) for 24 hours to induce maturation. The data are 
representative of at least three independent studies.Arthritis Research & Therapy    Vol 8 No 6    Shoda et al.
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Several dendritic cell-derived cytokines, such as IL-12, IL-18,
and IL-23, are known activators of T cells and important
cytokines in the pathogenesis of autoimmune diseases. CD4+
T cells increased IL-32 expression in response to IL-12 + IL-
18 and IL-23 stimulation (Figure 1d). In contrast, CD8+ T cells
did not increase IL-32 expression (data not shown). Moreover,
TNFα also increased IL-32 expression significantly in CD4+ T
cells (Figure 1d).
We also generated human MoDCs from CD14+ PBMCs.
Although immature control MoDCs hardly expressed IL-32,
LPS-stimulated MoDCs and, especially, TNFα-stimulated
MoDCs showed a significant increase of IL-32 expression
(Figure 1e). In this way, several kinds of immune cells, includ-
ing T cells, B cells, monocytes, and dendritic cells, were
shown to express IL-32, especially in activated states. Moreo-
ver, reciprocal IL-32 induction by TNFα was observed in CD4+
T cells and MoDCs.
Abundant IL-32 expression in the synovial-infiltrated 
lymphocytes of rheumatoid arthritis patients
To examine the pathological roles of IL-32 in RA, we tested IL-
32 expression in the synovial tissues of RA patients by in situ
hybridization (Figure 2a). We detected abundant IL-32 expres-
sion in the synovial-infiltrated lymphocytes of RA patients
rather than in the synovial lining cells. We could not detect the
IL-32 expression in the synovial lining layers, where monocytes
and synovial fibroblasts usually exist. Synovial fibroblasts pro-
duce cytokines and proteases, which play an important role in
joint inflammation [32]. We examined the IL-32 expression of
the synovial fibroblasts derived from four RA patients in vitro.
The synovial fibroblasts expressed IL-32 significantly after the
stimulation of TNFα (Figure 2b). This result suggested the
potential contribution of IL-32 to the joint inflammation medi-
ated by synovial fibroblasts.
Cytokine expression of the bone marrow chimera mice 
of IL-32β
Activated macrophages are known to be important sources of
the inflammatory cytokines in the joints of arthritis patients. hIL-
Figure 2
IL-32 was abundantly expressed in the synovial tissues of rheumatoid arthritis patients IL-32 was abundantly expressed in the synovial tissues of rheumatoid arthritis patients. (a) In situ hybridization of the synovial tissues from rheuma-
toid arthritis (RA) patients. IL-32β was expressed in the synovial-infiltrated lymphocytes of RA patients. HE stain, hematoxylin and eosin stain. We 
examined the tissue samples from four RA patients, and show representative examples. (b) IL-32 expression of the synovial fibroblasts derived from 
four RA patients in response to human tumor necrosis factor alpha (hTNFα).Available online http://arthritis-research.com/content/8/6/R166
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32 was reported to induce TNFα in the mouse macrophage
cell line Raw 267.4 [13]. We next confirmed the function of IL-
32 with our retroviral construct, MIG-hIL-32β. We choose IL-
32β for our assay because IL-32β was reported as a dominant
variant and a secreted protein from the cells [13]. The mouse
macrophage cell line Raw 267.4 was cultured with the super-
natants of MIG-hIL-32β-transfected cells. After 24 hours, the
mRNA expression of TNFα was increased by the stimulation
of hIL-32β (Figure 3a). In addition, the protein levels of TNFα
were increased in the supernatants of hIL-32β-stimulated cells
(Figure 3a).
To examine the proinflammatory effect of constitutively
expressed IL-32 in vivo, we prepared BM-hIL-32 mice. Six
weeks to 9 weeks after the bone marrow transplantation,
approximately 15% of the cells were GFP-positive in the thy-
mus and the spleen of the BM-hIL-32 mice (Figure 3b). The
GFP expression of CD4+ cells, CD8+ cells, CD11c+ cells,
CD19+ cells, and F4/80+ cells was also analyzed. There was
no significant difference in specific cellular components or the
percentage of GFP expression between mock mice and BM-
hIL-32 mice (data not shown). hIL-32β expression in the
spleen of BM-hIL-32 mice was also confirmed by quantitative
real-time PCR and in situ hybridization (data not shown).
In accordance with the data of cell lines, freshly isolated splen-
ocytes of BM-hIL-32 mice showed increased expression and
secretion of TNFα, compared with those of BM-Mock mice
(Figure 3c). We observed no increased expression and secre-
tion of IL-1β or IL-6 in freshly isolated splenocytes of BM-hIL-
32 mice. The serum concentration of TNFα protein was ele-
vated significantly in BM-hIL-32 mice (Figure 3d). The serum
concentration of IL-1β or IL-6 protein was not detected in BM-
hIL-32 mice, in BM-Mock mice, or in control mice. Cell sorting
analysis of splenocytes of BM-hIL-32 mice revealed that the
expression of TNFα was increased in freshly isolated F4/80+
macrophages (Figure 3e). Other cellular components (that is,
CD4+ cells, CD8+ cells, CD11c+ cells, or CD19+ cells) did not
show any significant change of the expression of TNFα (data
not shown). Although the serum TNFα concentration of BM-
hIL-32 mice was comparable with that reported for human
TNFα transgenic mice [1], no evident inflammation was
observed in histological examination of the spleen, the joint,
the intestine, the kidney, and the liver (data not shown).
We next examined the response of splenocytes of BM-hIL-32
mice to LPS stimulations. When cultured with LPS for 2 days,
splenocytes of BM-hIL-32 mice showed markedly increased
expression and secretion of TNFα and IL-1β (Figure 3c).
Among F4/80+ macrophages, CD11c+ dendritic cells, CD19+
B cells, CD4+ T cells, and CD8+ T cells from the spleen, both
F4/80+ macrophages and CD11c+ dendritic cells showed an
increased expression of TNFα and IL-1β after LPS stimulation
in the splenocytes of BM-hIL-32 mice (Figure 3f and data not
shown). We also observed that LPS-stimulated splenocytes of
BM-hIL-32 mice showed an increased secretion of IL-6 pro-
tein (Figure 3c), and F4/80+  macrophages showed an
increased expression of IL-6 (Figure 3f). Notably, purified
splenic CD4+ T cells from BM-hIL-32 mice did not show any
change in cytokine expression, including TNFα, IFN-γ, IL-1β,
IL-4, IL-6, and IL-17A (data not shown). In addition, splenocyte
proliferation induced by LPS or anti-CD3 antibody was no dif-
ferent between BM-hIL-32 mice and BM-Mock mice (data not
shown).
These results suggested that the function of in vivo expressed
IL-32β was focused on the induction of TNFα production,
especially in the macrophages. Our results also suggested
that in vivo expressed IL-32β collaborated with TLR4 signaling
to induce IL-1β and IL-6 production in macrophages and den-
dritic cells.
Exacerbation of TNFα-related inflammation in BM-hIL-32 
mice
We next examined the association of in vivo expressed IL-32β
with TNFα-related inflammation. We prepared two kinds of
murine models of inflammatory diseases – collagen antibody-
induced arthritis and TNBS-induced colitis. We induced arthri-
tis by administration of monoclonal antibodies to type II colla-
gen and administration of LPS to BM-hIL-32 mice. After
administration of LPS, more severe arthritis developed in BM-
hIL-32 mice than in BM-Mock mice in the early phase of the
disease (Figure 4a). This result was consistent with the in vitro
data, which showed that LPS stimulation induced a larger
amount of TNFα from splenocytes of BM-hIL-32 mice.
TNBS-induced colitis is a model of IBDs, in which TNFα plays
an important role. BM-hIL-32 mice showed more severe loss
of body weight than BM-Mock mice after the administration of
TNBS (Figure 4b). The histological scores were significantly
higher in BM-hIL-32 mice than in BM-Mock mice (Figure 4c).
The expression of hIL-32β mRNA was clearly increased in the
inflamed intestinal lesions of BM-hIL-32 mice but could not be
detected in BM-Mock or control mice by quantitative PCR
(data not shown).
Human TNF receptor p80 Fc fusion protein, known as etaner-
cept, neutralized the action of mouse TNFα and ameliorated
disease progression in collagen-immunized mice [8,33].
Although etanercept is reported as less effective in treating
Crohn's disease, the efficacy of etanercept in treating refrac-
tory Crohn's disease patients has been demonstrated [34,35].
We confirmed the efficacy of an increased dose of etanercept
to TNBS-induced colitis C57BL/6 mice as a preliminary study
(data not shown). When etanercept was administered to
TNBS-treated BM-hIL-32 mice just after the onset of colitis,
the severity of body weight loss was ameliorated (Figure 4b).
In vivo expressed IL-32 was therefore supposed to play an
important role in the exacerbation of colitis, in part through the
TNFα-inducing effect. The expression of TNFα was markedlyArthritis Research & Therapy    Vol 8 No 6    Shoda et al.
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Figure 3
Inflammatory cytokines were induced by human IL-32β in mice Inflammatory cytokines were induced by human IL-32β in mice. (a) Raw 267.4 was cultured with the supernatant of human IL-32β (h IL-32β) or 
mock-transfected mammalian cells (293T) for 24 hours. Left, relative expression of mouse tumor necrosis factor alpha (mTNFα), compared with β-
actin; right, secreted TNFα protein level measured by ELISA. (b) We generated hIL-32β overexpressed mice by transplantation of hIL-32β-trans-
duced bone marrow cells. The expression of green fluorescent protein, was analyzed by flow cytometry 6–9 weeks after transplantation. (c) Expres-
sion of mTNFα, mIL-1β and mIL-6 in the cultured splenocytes of the control group (white bars; n = 3), or bone-marrow chimeric mice of the mock 
group (BM-Mock mice) (gray bars; n = 4), or hIL-32β (BM-hIL-32) (black bars; n = 4) with or without 1 μg/ml lipopolysaccharide (LPS). Concentra-
tions of indicated cytokines of the cultured supernatants are shown in the right-hand figures. (d) Serum concentration of mTNFα determined in con-
trol mice (n = 4), in BM-Mock mice (n = 8), and in BM-hIL-32 mice (n = 8). (e) Expression of mTNFα in splenic F4/80+ CD11c- macrophages of BM-
Mock mice (gray bars; n = 4) and in BM-hIL-32 mice (black bars; n = 4). (f) Expression of mTNFα, mIL-1β, and mIL-6 in LPS-stimulated splenic F4/
80+ CD11c- macrophages and CD11c+, CD3-, and CD19- dendritic cells in BM-Mock mice (gray bars; n = 4), and in BM-hIL-32 mice (black bars; n 
= 4). Data are representative of at least three independent studies. *P < 0.05, **P < 0.01, BM-hIL-32 mice versus BM-Mock mice or control mice.Available online http://arthritis-research.com/content/8/6/R166
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increased in the rectal tissues of BM-hIL-32 mice, compared
with BM-Mock mice or with etanercept-treated mice (Figure
4d). In this way, TNFα-related inflammation was exacerbated
by overexpression of hIL-32β in the mouse model, and the
proinflammatory effects of hIL-32β were demonstrated in the
in vivo model.
Exacerbation of collagen-induced arthritis by transfer of 
IL-32β-transduced CD4+ T cells
Since synovial-infiltrated lymphocytes strongly expressed IL-
32, and peripheral CD4+ T cells significantly expressed IL-32,
we supposed CD4+ T cells to be one of the important sources
of IL-32 in the pathogenesis of inflammatory arthritis. To exam-
ine the proinflammatory effects of IL-32 produced by CD4+ T
cells, we transduced the hIL-32β gene to CD4+ T cells with a
retrovirus vector. We transferred these cells to bovine type II
collagen-immunized mice before the onset of arthritis. The
mice group to which the hIL-32β-transduced CD4+ T cells had
been transferred developed arthritis earlier than the mock
group of mice and showed significantly higher arthritis scores
(Figure 5a). Histological investigation of the joints showed sig-
nificantly severe cell infiltration in the hIL-32β group of mice
(Figure 5b). In this way, hIL-32β produced by CD4+ T cells
exacerbated arthritis in the mouse model.
In addition, a TNFα blockade by etanercept canceled the
proarthritic effects of hIL-32β according to the clinical and
pathological scores (Figure 5). IL-32-producing CD4+ T cells
were therefore supposed to play an important role in the exac-
erbation of the inflammatory arthritis, in part through a TNFα-
inducing effect. The proinflammatory effects of IL-32 were
therefore generally dependent on the TNFα-inducing effect in
these mouse models of inflammatory diseases.
Discussion
TNFα is a potent proinflammatory cytokine related to the
pathogenesis of inflammatory diseases such as RA and IBDs
[5,6,11]. The precise mechanism of TNFα induction in the
inflammatory diseases, however, is still unclear. We have
shown in the present article that in vivo expression of the novel
cytokine hIL-32 induced TNFα production, and that overex-
pressed IL-32β significantly exacerbated the mouse model of
Figure 4
Exacerbation of murine models of tumor necrosis factor alpha-related inflammatory diseases in BM-hIL-32 mice Exacerbation of murine models of tumor necrosis factor alpha-related inflammatory diseases in BM-hIL-32 mice. (a) Collagen-antibody-induced 
arthritis was induced in bone-marrow chimeric human IL-32β mice (BM-hIL-32) (n = 6) and bone-marrow chimeric mice of the mock group (BM-
Mock) (n = 4). Mean arthritis scores are shown. (b) Body weight change after induction of trinitrobenzen sulfonic acid (TNBS)-induced colitis in BM-
Mock mice (n = 7), in BM-hIL-32 mice (n = 4), and in BM-hIL-32 mice + 200 μg/day intraperitoneal administration of etanercept (n = 4). Control 
mice (n = 5) were administered only 50% ethanol with PBS. Percentage of initial body weight is shown. (c) Histological scores of TNBS-induced 
colitis. (d) Relative expression of mouse tumor necrosis factor alpha (mTNFα) in the colon of TNBS-induced colitis mice. *P < 0.05, **P < 0.01, BM-
hIL-32 mice versus BM-Mock mice or BM-hIL-32 mice + etanercept.Arthritis Research & Therapy    Vol 8 No 6    Shoda et al.
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arthritis and colitis. These results suggest that IL-32 plays an
important role in the exacerbation of inflammatory diseases.
IL-32 has been reported an inducer of TNFα and other inflam-
matory cytokines in vitro [13]. Joosten and colleagues
reported that the magnitude of IL-32 expression in the synovial
tissues was related to the RA severity, and that recombinant
hIL-32γ induced the joint inflammation in wild-type mice, which
was suppressed in TNFα-deficient mice [16]. The in vivo
effects and targets of IL-32, however, are still under examina-
tion. Moreover, the question of whether IL-32 plays a patholog-
ical role in animal models other than arthritis has not been
addressed. Although the IL-32 receptor or mouse analog of IL-
32 have not so far been reported, hIL-32 had biological activ-
ities on a mouse cell line and evoked joint inflammation in mice
[13,16]. We therefore examined the in vivo effects of hIL-32β
on bone marrow chimeric mice. We demonstrated the strong
association of in vivo expressed IL-32 with TNFα production
in the splenocytes, especially F4/80+ macrophages. Spleno-
cyte proliferation to the anti-CD3 antibody or LPS stimulation
was not affected by the in vivo expression of IL-32β (data not
shown). The CD4+ T cells did not change cytokine expression
in the presence of IL-32β. Therefore IL-32β had effects on
macrophages rather on than T cells in vivo, and the in vivo
roles of IL-32β were mainly to induce other inflammatory
cytokines rather than to activate the proliferation of the immune
cells. In the present study, we also demonstrated that the in
vivo overexpression of hIL-32β resulted in the exacerbation of
other mouse models of TNFα-related diseases – collagen-
induced arthritis and hapten-induced colitis. In addition, these
exacerbating effects of IL-32 were blocked by TNFα blockage,
which was consistent with Joosten and colleagues' work [16].
IL-1 and IL-6 are also crucial cytokines in arthritis [4]. Injection
of IL-1 into the normal joints of rabbits has caused severe
arthritis [36]. IL-1RA-deficient mice developed chronic inflam-
matory arthritis [37,38]. Anti-IL-1 antibody and IL-1 deficiency
ameliorated the mouse model of arthritis [39-41]. We have
shown that the expression and secretion of IL-1β and IL-6 was
increased in LPS-stimulated splenocytes from BM-hIL-32β
Figure 5
Transfer of human IL-32β-transduced CD4+ T cells exacerbated collagen-induced arthritis Transfer of human IL-32β-transduced CD4+ T cells exacerbated collagen-induced arthritis. Human IL-32β-transduced CD4+ T cells were transferred 
to collagen-immunized mice before the onset of arthritis (day 23). In one group (IL-32β + etanercept group), 50 μg/day etanercept was administered 
intraperitoneally for 14 days after transfer of CD4+ T cells. Each group consisted of 14 mice. (a) Arthritis scores and the percentage incidence of 
arthritis. (b) Cell infiltration, pannus formation, and bone erosion in CIA mice are quantified. Histological scores are shown as the mean ± standard 
deviation. *P < 0.05, **P < 0.01, IL-32β group versus mock group or IL-32β + etanercept group. ns, not significant.Available online http://arthritis-research.com/content/8/6/R166
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mice. IL-1β was expressed in CD11c+ dendritic cells, and IL-6
was expressed in F4/80+ macrophages after LPS stimulation.
IL-32 therefore induced IL-1β and IL-6 secretion in collabora-
tion with TLR4 stimulation in these cells. In parallel withthe in
vitro effect of LPS, disease models of BM-hIL-32 mice were
exacerbated in response to anticollagen antibodies and LPS
stimulation or TNBS administration. These results strongly
suggest that IL-32 functions in cooperation with other inflam-
matory signals in vivo. This induction of these proinflammatory
cytokines may be one of the important mechanisms of IL-32
leading towards inflammation. Although the previous report
did not demonstrate the synergizing effect of hIL-32 with Toll-
like receptor signaling in vitro [42], our results suggest that
continuous exposure to hIL-32 in relatively low concentrations
would have an influence on Toll-like receptor signaling of
splenocytes in vivo. Further studies are needed to clarify the
relationship between IL-32 and Toll-like receptor signaling,
however, and further studies are necessary for discerning the
actual mechanisms of IL-32 in the development of inflamma-
tory diseases.
Moreover, we demonstrated a reciprocal relationship between
TNFα and IL-32. TNFα induced the reciprocal expression of
IL-32 in various kinds of cells (namely CD4+ T cells, MoDCs,
and synovial fibroblasts). We suppose that a positive feedback
system between TNFα and IL-32 promotes the tissue inflam-
mation in the synovium and the intestinal epithelium. In this
way, IL-32 has a close relationship with the proinflammatory
cytokines, especially TNFα, and this relationship may be one
of the main mechanisms by which IL-32 promotes inflamma-
tion. Indeed, the proinflammatory effects of hIL-32β on colla-
gen-induced arthritis mice and TNBS-induced colitis mice
were, in part, canceled by a TNFα blockade.
It was reported that human TNFα transgenic mice spontane-
ously developed inflammatory arthritis [1]. Although the serum
TNFα concentration of BM-hIL-32 mice was comparable with
those of reported human TNFα transgenic mice [43], no
inflammatory change was observed in histological examination
of the joints (data not shown). It is suspected that this different
outcome occurred because BM-hIL-32 mice expressed the
transduced cytokine only in bone-marrow-derived cells, not in
fibroblasts or chondrocytes of the joints. There would there-
fore be no initiation of inflammation in the joints without the
infiltration of bone-marrow-derived cells expressing hIL-32.
The source of IL-32 remains unsolved. In our experiment, T
cells played a principal role in IL-32 production. In contrast to
B cells and monocytes, T cells expressed IL-32 mRNA in a
resting state. Moreover, activated T cells had the capacity to
induce IL-32 mRNA expression in B cells and monocytes. In
addition to TCR stimulation, IL-32 mRNA expression in CD4+
T cells is induced by various stimuli of inflammatory cytokines
related to RA. IL-12 + IL18 stimuli, IL-23 stimuli, and TNFα
stimuli increased IL-32 mRNA expression in CD4+ T cells.
Since the mRNA expression of IL-32 was induced by either
type of stimulation, IL-32 may be associated with the patholog-
ical roles of various dendritic cell-derived cytokines (namely IL-
12, IL-18, and IL-23) in inflammatory diseases. These results
suggested the capacity of CD4+ T cells to produce IL-32 in
response to a wide range of stimuli.
T cells are reported as important mediators in inflammatory
diseases, such as RA and IBDs. In terms of genetics, MHC
class II genes, especially the HLA-DR1 and DR4 subtypes, are
associated with RA sensitivity [44], and HLA-DRB1 is associ-
ated with Crohn's disease sensitivity [45]. In the mouse model
of colitis, Th1 cells were reported as important in the patho-
genesis of colitis. The colons of TNBS-treated mice were
marked by infiltration of CD4+ T cells exhibiting a Th1 pattern
of cytokine secretion. Administration of anti-IL-12 antibodies
led to a striking improvement of TNBS-induced colitis [46].
In animal models of arthritis, the transfer of CD4+ T cells from
SKG mice and IL-1Ra-deficient mice has evoked arthritis in the
recipient mice [38,47]. In particular, IL-17 production from
activated T cells is required for the development of destructive
arthritis in IL-1Ra-deficient mice [48]. Like the CD4+ T cells
from these animal models, IL-32β-producing CD4+ T cells
exacerbated collagen-induced arthritis. In RA synovium, IL-32
is principally expressed in infiltrated lymphocytes, which usu-
ally contain activated T cells [49]. We therefore speculate that
CD4+ T cells play an important role in the exacerbation of
inflammatory arthritis by means of IL-32 secretion. Notably, IL-
32 mRNA expression was detected in the synovial-infiltrated
lymphocytes. We supposed that IL-32-producing lym-
phocytes infiltrating the inflamed synovium participate in the
production of TNFα in the RA synovium.
This result does not exclude the possibility that a relatively low
amount of IL-32 is expressed in the synovial membranes of RA
patients, because the sensitivity of in situ hybridization is lim-
ited [50]. In the previous study, the synovial lining cells of RA
patients were stained by the anti-IL-32 antibody [16]. We
assumed that the phase or type of synovial inflammation was
different between Joosten and colleagues' patients and our
patients. In Joosten and colleagues' report, the synovial sam-
ples were obtained by percutaneous needle biopsy, and it is
suspected that their RA patients had active disease [16]. Our
samples, however, were obtained from patients in the pro-
gressed stage during total joint replacement surgery. In the
severely damaged joint, the cytokine-producing functions of
synovial lining cells are impaired [51]. We therefore suspected
that the expression of IL-32 could not be detected in the syn-
ovial lining cells by in situ hybridization in our study. Another
explanation is the difference of types of RA. The distribution of
IL-32 expression in synovial tissues may be dependent on the
type of RA, a matter that needs to be examined further.Arthritis Research & Therapy    Vol 8 No 6    Shoda et al.
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Conclusion
IL-32 mRNA was expressed mainly in the lymphoid tissues and
in a broad range of immune cells, including CD4+ T cells. In RA
patients, abundant IL-32 mRNA expression was observed in
the synovial-infiltrated lymphocytes. Splenic macrophages of
hIL-32β-overexpressed mice showed increased expression
and secretion of TNFα and IL-6, and splenic dendritic cells
showed increased expression and secretion of IL-1β in
response to LPS stimulation. Overexpression of hIL-32β also
resulted in the exacerbation of collagen antibody-induced
arthritis and TNBS-induced colitis. IL-32β-producing CD4+ T
cells significantly exacerbated inflammatory arthritis in the
mouse model. The effects of IL-32 in different disease models
were almost canceled by TNFα blockade.
This is the first study that demonstrated the in vivo cytokine-
inducing effects of IL-32. In addition, the reciprocal induction
between IL-32 and TNFα was also demonstrated in many
types of cells. IL-32 therefore has a close relationship with
TNFα, contributes to the exacerbation of inflammatory dis-
eases, and could be a new therapeutic target of these inflam-
matory diseases.
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